Integer Holdings Corporation announced that independent Board Chair Pamela G. Bailey will not seek re-election at the May 20, 2026 Annual Meeting. Donald J. Spence, a director since 2016 and former CEO of Ebb Therapeutics and Lake Region Medical, will be appointed as the new independent Chair following the meeting.

Integer Holdings Corporation's stock has declined 28% over the past year. VP Corporate Controller Tom Thomas sold 825 shares worth $70,000 on March 13, 2026, representing 15.85% of his direct holdings. The article characterizes this as routine liquidity management rather than a loss of confidence. Despite revenue growth of 8% YoY to $1.85 billion in 2025, the company faces elevated leverage near 3.0x EBITDA, with investors focused on whether Integer can sustain margin expansion and balance sheet improvement.

Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes for allegedly making false statements about uranium enrichment technology; Integer Holdings for overstating competitive position and concealing sales deterioration; Molina Healthcare for failing to disclose adverse medical cost trends; and Soleno Therapeutics for misrepresenting the safety profile of its drug candidate DCCR, which resulted in a patient death.

Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes for allegedly making false statements about uranium enrichment technology; Integer Holdings for overstating competitive position and concealing sales deterioration; Soleno Therapeutics for misrepresenting safety profile of drug candidate DCCR/VYKAT XR; and Unicycive Therapeutics for overstating FDA manufacturing compliance readiness. Shareholders who purchased shares during specified periods may be eligible to seek corporate reforms and compensation.

Integer Holdings Corporation announced the appointment of James Flanagan and Aaron Kapito to its Board of Directors as independent directors. Aaron Kapito's appointment is connected to a cooperation agreement with investment firm Irenic Capital Management. The moves are intended to enhance Integer's focus on growth and value creation, with the company expecting organic sales growth to return to market levels in 2026 and above-market growth in 2027.

Grabar Law Office is investigating shareholder claims against four companies for alleged breaches of fiduciary duties and securities fraud. Corcept Therapeutics faces allegations of misrepresenting clinical trial data for its relacorilant drug, which received an FDA Complete Response Letter. Integer Holdings is accused of overstating its competitive position and concealing deteriorating sales. Kyndryl Holdings disclosed SEC investigations into cash management practices and internal control weaknesses. Molina Healthcare allegedly failed to disclose adverse medical cost trends and guidance risks.

Integer Holdings Corporation announced that its executive leadership team will participate in three major investor conferences in March 2026: Raymond James 47th Annual Institutional Investors Conference (March 3), Oppenheimer 36th Annual Healthcare MedTech & Services Conference (March 17), and KeyBanc Capital Markets Healthcare Forum (March 18). Live webcasts and replays will be available on the company's investor relations website.

Irenic Capital Management sold 1,047,583 shares of Surgery Partners (SGRY) in Q4 2025, reducing its stake to just 0.09% of assets. The stock has declined 39.7% over the past year, underperforming the S&P 500 by 51.61 percentage points. While the company's operations remain solid with 6.6% revenue growth, concerns center on high leverage with net debt to EBITDA at 4.2x-4.6x in a higher rate environment.

Irenic Capital Management LP significantly reduced its Papa John's International position by approximately 70%, selling 748,592 shares in Q4 and retaining only 325,108 shares valued at $12.5 million. The stake now represents just 0.8% of the fund's AUM, dropping out of its top five holdings. Papa John's stock has underperformed the market, declining 30.7% over the past year while the S&P 500 gained 16.4%, amid struggling North American same-store sales.

Integer Holdings (ITGR) stock rose over 2% on Friday following strong Q4 2025 earnings results and multiple analyst upgrades. Benchmark upgraded the stock to buy with a $95 price target, while Wells Fargo and Truist Securities raised their price targets. The company reported 5% year-over-year sales growth to $472 million and a 22% increase in non-GAAP net income to $62 million.

A securities class action lawsuit has been filed against Integer Holdings Corporation for allegedly making materially false and misleading statements about its competitive position in the electrophysiology manufacturing market and overstating the growth potential of its EP devices. Investors who purchased Integer common stock between July 25, 2024 and October 22, 2025 may be entitled to compensation. The deadline to serve as lead plaintiff is February 9, 2026.

A class action lawsuit has been filed against Integer Holdings Corporation (NYSE:ITGR) for securities fraud, alleging the company overstated demand for its electrophysiology devices while actual sales fell sharply. The stock dropped 32% on October 23, 2025, after Integer lowered its 2025 guidance and admitted to slower-than-forecasted adoption of two EP devices. Investors have until February 9, 2026, to join the lawsuit.